Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREVI-OC-02: torvutatug samrotecan plus bevacizumab versus bevacizumab maintenance in first-line HRD-negative advanced ovarian cancer
MOH_2026-08-11_016978Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Torvutatug samrotecan + bevacizumab with Bevacizumab (2 arms). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
torvutatug samrotecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2026-08-11_016978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-11_016978.